Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death and is driven mostly by mutated Kras gene. Despite advances in our understanding of the pathogenesis of PDAC, the disease remains highly refractory to treatment. In this proposal, we will employ genome scale approaches to identify potential signaling nodes and druggable targets that will be used for therapeutics development for PDAC patients. Based on our preliminary data and technical capabilities, we proposed the following specific aims.
Aim #1) To identify co-extinction targets for combination therapeutics against KRAS* PDAC. The goal of this aim is to identify candidate targets that when co-extinguished can lead to suppression or death of KRAS* PDAC tumor cells. Both genetic and pharmacological approaches will be used, taking advantage of strengths of both mouse and human systems, as well as leveraging the emerging comprehensive genomic data on human PDAC. Co-extinction target candidates identified in more than one system will be prioritized for in-depth biological, functional as well as clinical pathological validation.
Aim #2) To identify resistance mechanism to KRas inhibition. The goal of this aim is to proactively anticipate and elucidate possible molecular basis for resistance in setting of Kras* inhibition. We will apply a novel in vivo context-specific genetic screen approach to identify and functionally validate genes that promote survival of PDAC cells following KRas inactivation, initially focusing on the kinases followed by genetic elements of interests defined by comprehensive genomics by ICGC PDAC project. Furthermore, we will engineer GEM models with the most promising resistant hits to validate resistance mechanism in vivo and to test new therapeutic strategy against such resistance mechanisms.
Pancreatic cancer remains incurable despite advances in our understanding of its pathogenesis. In this proposal, we will employ various state of the art technologies to identify therapeutic intervention points that will lead to cell death or proliferation arrest of KRas driven pancreatic cancer cells.
|Kapoor, Avnish; Yao, Wantong; Ying, Haoqiang et al. (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158:185-97|
|Sahora, Klaus; Fernández-del Castillo, Carlos; Dong, Fei et al. (2014) Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery 156:611-21|
|Mayers, Jared R; Wu, Chen; Clish, Clary B et al. (2014) Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 20:1193-8|
|Lee, John J; Perera, Rushika M; Wang, Huaijun et al. (2014) Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A 111:E3091-100|
|Deschênes-Simard, Xavier; Lessard, Frédéric; Gaumont-Leclerc, Marie-France et al. (2014) Cellular senescence and protein degradation: breaking down cancer. Cell Cycle 13:1840-58|
|Daver, Naval; Shastri, Aditi; Kadia, Tapan et al. (2014) Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38:1126-9|
|Viale, Andrea; Pettazzoni, Piergiorgio; Lyssiotis, Costas A et al. (2014) Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514:628-32|
|Lyssiotis, Costas A; Cantley, Lewis C (2014) Targeting metabolic scavenging in pancreatic cancer. Clin Cancer Res 20:6-8|
|Commisso, Cosimo; Davidson, Shawn M; Soydaner-Azeloglu, Rengin G et al. (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497:633-7|
|Lyssiotis, Costas A; Son, Jaekyoung; Cantley, Lewis C et al. (2013) Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle 12:1987-8|
Showing the most recent 10 out of 48 publications